...
首页> 外文期刊>RMD Open >Original article: Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
【24h】

Original article: Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience

机译:原始文章:系统性红斑狼疮的糖皮质激素停药:缓解和疾病活动低下是否是停止治疗的可靠起点?真实体验

获取原文
           

摘要

Objectives To evaluate the proportion of patients who have successfully withdrawn glucocorticoids (GCs) in a longitudinal cohort of patients with systemic lupus erythematosus (SLE) over a period of 6 years; to evaluate patient characteristics during GC withdrawal in relation to existing definitions of remission and Lupus Low Disease Activity State (LLDAS); and to evaluate the occurrence of flares after GC withdrawal.Methods Patients who attempted GC withdrawal were identified for the cohort, and the following information was assessed during withdrawal attempts: date of last disease flare, disease activity and damage and ongoing treatment. Information regarding the occurrence of disease flares after GC withdrawal was also recorded for patients who successfully stopped treatment.Definitions of remission were applied to GC withdrawal in line with European consensus criteria (Definitions of remission in SLE [DORIS]) and LLDAS in line with the Asian Pacific Lupus Consortium definition.Results 148 patients were involved in the study; GC withdrawal was attempted in 91 patients (61.5%) with 77 patients (84.6%) successfully stopping GCs. At the beginning of the GC reduction, the majority of patients were in complete or clinical remission (48.9% and 39.6%, respectively). Disease activity was significantly lower in patients who successfully stopped GCs, and the proportion of patients in complete remission was higher (54.2%) with respect to patients who failed in their attempt. Among patients who stopped GCs, 18 flares were recorded after a median of 1 year. The time period since the last flare was shorter in patients who experienced flares with respect to patients who did not flare (mean 0.93 years vs 6.0, p0.001).Conclusions GC withdrawal is an achievable goal in SLE and may be attempted after a long-term remission or LLDAS to protect the patient from disease flares.
机译:目的评估过去6年中系统性红斑狼疮(SLE)患者纵向队列中成功撤出糖皮质激素(GCs)的患者比例;与现有缓解和狼疮低病活动状态(LLDAS)定义相关的GC停药期间评估患者特征;方法鉴定尝试撤离胃癌的患者,并在撤离尝试中评估以下信息:上次疾病发作的日期,疾病活动和损害的程度以及正在进行的治疗。还记录了成功停止治疗的患者停药后发生疾病发作的信息。根据欧洲共识标准(SLE [DORIS]中的缓解定义)和LLDAS符合欧洲共识标准,对停药进行了缓解定义。结果148名患者参与了研究;尝试撤消91例患者(61.5%)中的GC,成功终止GC的患者77例(84.6%)。在降低GC的开始阶段,大多数患者已完全缓解或临床缓解(分别为48.9%和39.6%)。成功终止GC的患者的疾病活动性显着较低,并且完全缓解的患者比例相对于尝试失败的患者较高(54.2%)。在停止使用GC的患者中,中位1年后记录了18次耀斑。相较于没有发作的患者,经历了发作的患者自上次发作以来的时间较短(平均0.93年vs 6.0,p <0.001)。结论GC撤药是SLE中可实现的目标,可能需要较长时间才能尝试长期缓解或LLDAS,以保护患者免于疾病发作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号